Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | TCF7 | P36402 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634568 | 0.86 | CACNA1H (0.44) | HTR2AHTR2CCACNA1HSLC5A2RECQL | |
| SCHEMBL904726 | 0.83 | SLC5A2 (0.46) | HTR2AHTR2CCACNA1HSLC5A2RECQL | |
| SCHEMBL27931203 | 0.81 | CACNA1H (0.41) | HTR2AHTR2CCACNA1HSLC5A2RECQL | |
| SCHEMBL904802 | 0.80 | HTR2A (0.39) | HTR2AHTR2CCACNA1HRECQLHTR2B | |
| SCHEMBL904775 | 0.80 | MAOB (0.49) | HTR2AHTR2CCACNA1HHTR2BQPCT | |
| SCHEMBL29728749 | 0.79 | CTNNB1 (0.54) | HTR2ACACNA1HCTNNB1TCF7 | |
| SCHEMBL213305 | 0.79 | CHEK1 (0.53) | HTR2AHTR2CCACNA1HHASPINKMO | |
| SCHEMBL904751 | 0.79 | CTNNB1 (0.54) | HTR2ACACNA1HCTNNB1TCF7 | |
| SCHEMBL17316596 | 0.78 | KDM4E (0.54) | CACNA1HTRPM8KMO | |
| SCHEMBL7071662 | 0.77 | KMO (0.45) | HTR2AHTR2CHASPINKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829026-B2 | Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20130210858-A1 | SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2013-08-15 | — | — | US | disclosed |
| WO-2012042915-A1 | SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210858-A1 | SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM6, TRPM5 | HTR2A 455/4885HTR2C 633/4885CACNA1H 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.